IPCXR vs TECH · rev $100.0M vs P/E 65, rev $1.22B
Inflection Point Acquisition Corp. III Rights (IPCXR) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Inflection Point Acquisition Corp. III Rights (IPCXR) common stock listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported IPCXR revenue for 2025-09-30 was $100.0M. Net income was -$90.8K. IPCXR currently screens at market cap $0.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
IPCXR currently screens at market cap $0. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the IPCXR and TECH stock pages for the full models.
Not investment advice.